Ozempic Patent Expiration: 5 Essential Dates to Know

Ask when Ozempic goes generic and you will get a different answer from every headline — 2026, 2031, even 2032. They are all partly right, which is the problem. Ozempic patent expiration is not one date but a stack of patents and regulatory exclusivities that lift at different times. Novo Nordisk’s blockbuster is protected by dozens of US patents, and the one that matters for cheap generic semaglutide is not the one that expires first. Here is how the stack actually works, drawn straight from the FDA’s Orange Book.

Ozempic Patent Expiration: The Short Answer

Two compound patents cover semaglutide, the active ingredient in Ozempic and Wegovy. The first, US Patent No. 8,536,122, expired on 20 March 2026. The second and more important one, US Patent No. 8,129,343, runs to 5 December 2031 after a patent term extension for regulatory delay. Until that second patent falls, a true generic semaglutide cannot launch in the United States.

So the honest answer to “when does Ozempic go generic in the US?” is: not before late 2031, and realistically 2032 once you account for the dance between Novo Nordisk and generic applicants. The 2026 date you may have read about is real, but it is the weaker of the two compound patents and does not open the door on its own.

• US 8,536,122 (compound) — expired 20 March 2026
• US 8,129,343 (compound) — expires 5 December 2031 (with term extension)
• Latest listed patent, US 11,318,191 — expires 17 February 2041
• FDA marketing exclusivities — extend into 2029

The Two Compound Patents That Matter Most

A compound (or composition-of-matter) patent is the strongest protection a drug can have, because it covers the molecule itself. No competitor can sell that molecule, in any formulation, while it stands. That is why the December 2031 expiry of US 8,129,343 is the real gatekeeper for generic semaglutide, not the earlier 2026 patent.

The reason the two compound patents expire five years apart is patent term extension. US law restores part of the patent life lost while a drug sits in FDA review, which is why the 343 patent was effectively pushed out to the end of 2031. If you want the mechanics, see our explainer on patent term extension — it is the single factor that most often moves a drug’s real cliff by years.

Novo Nordisk has already received notices that several manufacturers filed Abbreviated New Drug Applications (ANDAs) to sell generic semaglutide. Filing an ANDA does not mean a generic can launch — it starts the litigation that decides whether, and exactly when, it can.

Beyond 2031: Formulation, Device and Use Patents

The compound patent is not the end of the story. The Orange Book lists dozens of patents across Novo Nordisk’s semaglutide products — more than forty across the injectable and oral versions of Ozempic and Wegovy. They cover the specific formulation, the dosing regimen, and the injection pen, and they run out to 2032, 2033, 2038 and as late as 17 February 2041 for US 11,318,191.

These secondary patents rarely block a generic of the same molecule, because a generic maker can often design around a formulation or device patent while still copying the drug. But they can shape what a generic looks like and spark side disputes. This layered strategy — a core molecule patent surrounded by a thicket of later ones — is standard in pharma and a textbook driver of the broader pharma patent cliff.

Regulatory Exclusivity Is Not the Same as a Patent

Patents and FDA exclusivity are two separate clocks, and people routinely confuse them. A patent is granted by the USPTO and can be challenged or designed around. FDA exclusivity is a marketing protection granted under the Food, Drug, and Cosmetic Act that simply bars the agency from approving a competitor for a set period, regardless of the patent position.

For semaglutide, new-indication and new-strength exclusivities extend into 2029. Those do not override the 2031 compound patent — the patent is the later and higher wall — but on other drugs an exclusivity period can be the real barrier even after the patents lapse. Always check both clocks before predicting a launch date.

Why the Expiry Date Is Not the Launch Date

Patent expiration sets the earliest theoretical date a generic can arrive. The actual date depends on litigation, settlements, manufacturing readiness and the FDA approval queue. Under the Hatch-Waxman framework, a generic applicant that challenges a patent can trigger a 30-month stay and years of court fights; the parties often settle on an agreed entry date that is earlier than the patent expiry but later than the generic hoped.

1. A generic files an ANDA, often with a challenge to the listed patents.
2. The brand sues, which can freeze FDA approval for up to 30 months.
3. The case is litigated or, more often, settled on a negotiated launch date.
4. The generic must also clear FDA manufacturing and approval before it can ship.

That is why analysts point to 2032 — not 2031 — as the practical arrival of generic semaglutide in the US, and why any confident single date deserves a raised eyebrow. Valuing a drug through this maze is its own discipline; our guide on how to value a drug patent walks through it.

Outside the US: The Cliff Arrives Sooner

Patent expiry dates are national, and semaglutide’s core protection lapses earlier in several other markets than it does in the United States. In Canada, India and Brazil, the principal semaglutide patent expires around 2026, which is why generic and locally made versions have been widely reported to be preparing for launch there well before any US generic is possible.

For a global brand, that staggered timeline is both a threat and a planning tool. It explains the surge of compounded and generic semaglutide activity outside the US while American patients still face brand-only pricing. For the fundamentals of how drug monopolies are built and defended across borders, see our overview of pharmaceutical patents.

What the Ozempic Cliff Means for You

If you are an investor, the headline risk is concentrated in late 2031, not 2026. If you are a generic or biosimilar developer, the compound patent and the ANDA litigation calendar are the gating items, and the secondary-patent thicket is a design-around exercise, not a wall. If you are a founder in any field, the lesson generalises: a single expiry date rarely tells you when a market opens.

The reliable move is to read the actual patent and exclusivity listings — for US drugs, the FDA’s Orange Book is the primary source — rather than trust a round number in a headline. The dates are public; the interpretation is where the value is.

This article is general information, not legal or investment advice; consult a qualified attorney for your situation.

How PerspireIP Can Help

PerspireIP helps pharmaceutical and life-sciences teams map patent cliffs, run freedom-to-operate and invalidity searches, and value drug portfolios across jurisdictions. Whether you are defending a franchise or planning a generic entry, we turn Orange Book listings into a clear timeline. Contact us to scope your analysis.

Frequently Asked Questions